Skip to Main Content

Paper Details

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
J Clin Oncol
34
2021
BRCA, BRCA mutations, HR, Human, Human Epidermal Growth Factor Receptor 2, MBC, Patients, breast, hormone receptor, human, human epidermal growth factor receptor 2, metastatic breast cancer, patient, patients, poly (ADP-ribose), poly (ADP-ribose) polymerase, programmed cell death ligand-1, triple-negative MBC, triple-negative, programmed cell death ligand
Author NameAffiliation
Nancy E DavidsonFred Hutchinson Cancer Research Center and University of Washington
Gabriel N HortobagyiMD Anderson Cancer Center
Rita NandaUniversity of Chicago
Kathryn J RuddyMayo Clinic
Lisa A CareyUNC Lineberger Comprehensive Cancer Center
  • 1 - 5

Datasets

Release 1.2